Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

Nurse sitting at desk using computer

Your severely immunocompromised (IC) patients may be eligible for a non-live shingles vaccination1,2

Help to protect your eligible patients by referring them for their non-live shingles vaccination1

From 1st September 2025, eligibility for shingles vaccination expands to include all severely immunocompromised individuals aged 18 and over.1,3

Given their risk of severe disease, the UK Health Security Agency has stated that the severely immunocompromised cohort (as defined in the Green Book) represents the highest priority for shingles vaccination within the Shingles National Immunisation Programme.1

Only 19.3% of eligible severely immunocompromised patients who turned 50 and over from 1st September 2023 to 31st August 2024, had received their first dose of their shingles vaccine by 23rd October 2024.4

Which of your severely immunocompromised patients should you refer to primary care for shingles vaccination?1,3

Eligible severely immunocompromised patients
(As defined in the Green book)1

  • Individuals receiving stem cell transplant

    • Receiving an allogeneic (cells from a donor) or an autologous (using their own cells) stem cell transplant
    • Receiving CAR-T (chimeric antigen receptor T-Cell) therapy

    • Acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin's lymphoma), who are less than 12 months since achieving cure 
    • Under follow up for chronic lymphoproliferative disorders including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom's macroglobulinemia and other plasma cell dyscrasias (N.B.: this list is not exhaustive)
    • Immunosuppression due to HIV/AIDS with a current CD4 count of below 200 cells/µl.
    • Primary or acquired cellular and combined immune deficiencies - those with lymphopaenia (<1,000 lymphocytes/µl) or with a functional lymphocyte disorder
    • Received an allogenic (cells from a donor) or an autologous (using their own cells) stem cell transplant in the previous 24 months
    • Received a stem cell transplant more than 24 months ago but have ongoing immunosuppression or graft versus host disease

    • Receiving or have received in the past 6 months immunosuppressive chemotherapy or radiotherapy for any indication
    • Receiving or have received in the previous 6 months immunosuppressive therapy for a solid organ transplant
    • Receiving or have received in the previous 3 months targeted therapy for autoimmune disease, such as JAK inhibitors or biologic immune modulators including
      • B-cell targeted therapies (including rituximab but for which a 6 month period should be considered immunosuppressive), this should be monocloncal tumour necrosis factor inhibitors (TNFi), T-cell co-stimulation modulators, soluble TNF receptors, interleukin (IL)-6 receptor inhibitors.
      • IL-17 inhibitors, IL 12/23 inhibitors, IL 23 inhibitors (N.B.: this list is not exhaustive)

    • Moderate to high dose corticosteroids (equivalent ≥ 20mg prednisolone per day) for more than 10 days in the previous month
    • Long term moderate dose corticosteroids (equivalent to ≥10mg prednisolone per day for more than 4 weeks) in the previous 3 months
    • Any non-biological oral immune modulating drugs in the previous 3 months
      • methotrexate >20mg per week (oral and subcutaneous)
      • azathioprine >3.0mg/kg/day
      • 6-mercaptopurine >1.5mg/kg/day
      • mycophenolate >1g/day
    • Certain combination therapies at individual doses lower than stated above, including those on ≥7.5mg prednisolone per day in combination with other immunosuppressants (other than hydroxychloroquine or sulfasalazine) and those receiving methotrexate (any dose) with leflunomide in the previous 3 months

    • equivalent to >40mg prednisolone per day for more than a week, for any reason in the previous month

Learn more about SHINGRIX

Illustrative icon of group of patients

What is the impact of shingles on IC patients?

IC patients are at increased risk of shingles and its complications compared to the general population1

IMPACT OF SHINGLES

White cross in red circle (Medical sign)

Learn more about SHINGRIX clinical trial data on IC patients

SHINGRIX has been investigated in a range of immunocompromised patient populations ≥ 18 years of age including solid tumours, haematologic malignancies, renal transplants and autologous haematopoietic stem cell transplants (auHSCT), includes post-hoc analyses.5-8

clinical trial data in IC patients

References

  1. UKHSA Green Book: Shingles (herpes zoster): the green book chapter
  2. SHINGRIX. Summary of product characteristics (UK)
  3. UK Health Security Agency. Shingles vaccination programme: expansion of Shingrix vaccine eligibility to all those who are severely immunosuppressed and aged 18 years and over. Published July 2025.
  4. UK Health Security Agency. Shingrix vaccine uptake report (adults eligible from September 2023 to August 2024 and vaccinated to the end of October 2024): England. Updated 31 July 2025.
  5. Bastidas A, de la Serna J, El Idrissi M, et al.; for the ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial [suppl]. JAMA. 2019 July;322(2):123-133.
  6. Dagnew AF, Ilhan O, Lee WS, et al.; on behalf of the Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019 September;19(9):988-1000.
  7. Vink P, Torelle JMR, Sanchez Fructuoso A, et al.; for the Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020 January;70(2):181-190.
  8. Vink P, Mignorance ID, Alonso CM, et al.; on behalf of the Zoster-028 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019 April;125(8):1301-1312.

Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2025 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

October 2025 | PM-GB-SGX-WCNT-230042 (V2.0)